IBD Center Features a Highly Specialized Team of Dedicated Experts

Through collaboration with USF Health, TGH patients have access to the USF Health Inflammatory Bowel Disease Center. One of the few academic medical centers that specialize in the diagnosis and treatment of inflammatory bowel disease (IBD), ulcerative colitis, and Crohn’s disease, the USF Health IBD Center features a highly specialized team of dedicated experts.

MULTIDISCIPLINARY APPROACH TO CARE

IBD is a complex disease state that has immunologic characteristics and often requires care from multiple providers in different specialties. A team of colorectal surgeons, gastroenterologists and nutritionists, as well as a dietitian and social worker, participate in monthly case meetings to create specialized care plans for patients with complex IBD-related conditions.

LED BY DEDICATED IBD GASTROENTEROLOGIST

Dr. Jennifer Seminerio, the IBD Center Director, is a fellowship-trained, board-certified gastroenterologist. Her practice is 100% dedicated to the diagnosis and treatment of IBD, as well as research studies to further the field. Dr. Seminerio is a national speaker and recognized IBD expert. She is also host of Florida IBD Live, a CME-accredited Zoom Conference dedicated to educating physicians about IBD treatments and case collaborations.

ROBUST RESEARCH PROGRAM

Gastroenterologists at the IBD Center participate in both investigator-initiated and industry clinical trials involving early-stage therapies and medications that may give hope to patients suffering with the most challenging IBD-related diseases. A funding grant of $1 million has allowed IBD Center specialists to continue research and further develop its standing as a center of excellence.

ACTIVE CLINICAL TRIALS:

• Corrona-IBD-600 Registry - Monitor patients who have started an approved biologic or JAK inhibitor for the first time within 12 months.
• Celgene Ozanimod 3202 Crohn’s - For patients with moderate to severely active CD and previous intolerance to corticosteroids, immunomodulators and biologics.
• Janssen 3001 UC - For patients with moderate to severely active UC, Mayo rectal bleeding score ≥ 1, screening endoscopy score ≥ 2.
• Tigenix ASC Crohn’s - This is a completed trial for patients with clinically controlled or mildly active CD, presence of perianal fistula with maximum of two internal and two external openings, inadequate response to TNF-a antagonist, vedolizumab or ustekinumab.
• Eli Lilly AMAM - For patients with moderate to severely active CD, previous intolerance to corticosteroids, immunomodulators and biologics.
• Tour Registry - This is a completed registry that monitored patients diagnosed with moderate-severe UC, who within two weeks have been started on tofacitinib or plan to start in the next two weeks.